Abstract submission is NOW OPEN through Jan. 31, 2025! Send us your research for possible presentation at the 28th Annual Meeting!
If you enjoy today’s conversation, you’ll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24.
Join ASGCT and the Molecular Therapy family of journals for a conversation between Drs. Paloma Giangrande and Marcin Kortylewski. They discuss a recent article published in Molecular Therapy Nucleic Acids by Dr. Kortylewski and colleagues titled "Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3."
This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolving field.
Register now for invaluable insights on navigating the regulatory landscape.
Dr. Paloma Giangrande Editor-in-Chief of Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapeutics
Dr. Marcin Kortylewski Professor, Department of Immuno-Oncology at City of Hope
'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au
November 19-20, 2024 | Chicago, IL
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico